The eIF1A Monoclonal Antibody (CAB20954) is a high-quality antibody developed for reliable detection and analysis of target proteins. This antibody, produced in rabbits, exhibits high reactivity with human samples and has been validated for use in Western blot applications. By binding specifically to EIF1A, researchers can detect and analyze this protein in various cell types, making it an ideal tool for studies in molecular biology and cancer research.EIF1A plays a crucial role in the translation initiation process, promoting the binding of the initiator tRNA to the small ribosomal subunit.
This antibody is validated for use in WB, ELISA applications and has demonstrated reactivity against Human, Mouse samples.
Product Name:
eIF1A Monoclonal Antibody
SKU:
CAB20954
Size:
20μL, 100μL
Reactivity:
Human, Mouse
Clone Number:
ARC2941
Conjugate:
Unconjugated
Immunogen:
Synthetic peptide. This information is considered to be commercially sensitive.
Recommended starting concentration is 1 μg/mL. Please optimize the concentration based on your specific assay requirements.
Synonyms:
EIF1A, EIF4C, eIF-1A, eIF-4C, EIF1AP1, eIF1A
Positive Sample:
HeLa, C2C12
Cellular Localization:
Cytoplasm, Cytosol, Synapse.
Calculated MW:
16kDa
Observed MW:
17kDa
This gene encodes an essential eukaryotic translation initiation factor. The protein is required for the binding of the 43S complex (a 40S subunit, eIF2/GTP/Met-tRNAi and eIF3) to the 5' end of capped RNA.
Purification Method
Affinity purification
Gene ID
1964
Buffer Information
Store at -20℃. Avoid freeze / thaw cycles. Buffer: PBS containing 50% glycerol and 0.05% BSA, preserved with proclin300 or sodium azide, pH 7.3.
Western blot analysis of various lysates using eIF1A Rabbit mAb (CAB20954) at 1:1000 dilution incubated at room temperature for 1.5 hours. Secondary antibody: HRP-conjugated Goat anti-Rabbit IgG (H+L) (CABS014) at 1:10000 dilution. Lysates/proteins: 25 μg per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Basic Kit (AbGn00020). Exposure time: 5 s.
